Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Novel Insights and Advanced Research on Lung Cancer and COPD
- COPD 2019


Lung Cancer and COPD Congress 2019:

The 6th International Congress on Lung Cancer and COPD was organized on November 20-21, 2019 at Berlin, Germany. The conference was marked with the attendance of Editorial Board Members of supported Allied Academies Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 15 countries, who made this conference fruitful and productive.

This conference was based on the theme “Novel Insights and Advanced Research on Lung Cancer and COPD” which included the following scientific tracks:  

·         Lung cancer

·         Stages & Severity on Lung Diseases

·         Chronic Obstructive Pulmonary Disease

·         Causes of COPD

·         Pathophysiology of Lung Cancer & COPD

·         Surgical and Radiation Oncology

·         Comorbidities of Pulmonary Diseases

·         Lung Diseases, Cancer & its Epidemiology

·         Diagnosis of COPD

·         Clinical Trials on COPD

·         Cancer Biology & Genetics

·         Lung Cancer & Therapeutics

·         Treatment strategies of COPD

·         Emerging genetics of Lung Cancer & COPD

·         Risk Assessments on Lung Diseases

·         Diagnosis of lung cancer

·         Prevention and Awareness on COPD


Lung Cancer and COPD Congress 2019 was moderated by Anatoly Verenchikov (Montenegro) on the first day.

We are grateful to our Organizing Committee Members for their generous support and suggestions for the conference.

  • Dejan Dokic, Saints Cyril and Methodius University of Skopje, Skopje, Macedonia
  • Claude Billeaud, CIC Pédiatrique 1401 CHU Pellegrin, France
  • Tsetlin V, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry- Russian Academy of Sciences, Russia
  • Anatoly Verenchikov, Mass Spectrometry Consulting Ltd., Montenegro

The conference proceeded through various Scientific Sessions and plenary lectures, of which the following topic was highlighted:

  • Disparities In Geographic Access To Hospital Outpatient Pulmonary Rehabilitation Programs In The United States: Ira Moscovice– University of Minnesota, USA

Scientific sessions were chaired by Claude Billeaud, Association Européenne pour l’Enseignement en Pédiatrie, France

Allied Academies has taken the grand privilege of felicitating Lung Cancer and COPD Congress 2019 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event.

The esteemed guests, Keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their presentations at the podium of Lung Cancer and COPD Congress 2019. We are glad to inform that all accepted abstracts for the conference be published in the Journal of Pulmonology and Clinical Research as a special issue.

With the unique and positive feedback from the conference, Allied Academies would like to announce the commencement of the "7th International Conference on COPD and Lung Health" which is being organized during June 11-12, 2020 at Valencia, Spain.

Welcome Message

The 6th International Conference on Lung cancer and COPD is the world’s largest educational and scientific conference, dedicated to lung cancer and pulmonary diseases hosted on November 20-21 2019 Berlin, Germany. The congress summarizes the recent developments and advancements in lung cancer, COPD and pulmonary diseases research. The attendees of the conference include Medical OncologistsPulmonologistsEpidemiologistsSurgeonsPathologists, Research Scientists, Respiratory Physicians, Health Care Professionals and representatives from the academic and industrial experts.

Why to attend Lung Cancer and COPD Congress 2019?

Lung Cancer and COPD Congress 2019 provides a golden opportunity to meet the leading national and international speakers who will discuss the latest advancements in Lung cancer treatment, COPD, Pulmonary Diseases worldwide. COPD Conference 2019 unites individuals or eminent personalities from all over the world, who share a common discipline in lung diseases research. This conference is a collaborative event for the researchers from both business and academia background and offers current and recent information on the management of lung cancer, as well as the possible therapies and strategies to shape the future of lung cancer and COPD research. We encourage physicians, nurses, researchers and scientists as well as patients in the lung cancer field and those interested in attending to this Conference. It is only through an exchange of the widest variety of research we can offer the best program and benefits to our members and patients.

Abstract Submission & Important Dates

Abstract Submission Guidelines: 

The length of the abstract must not exceed 300 words.

The title should be in sentence case.

Should write name of the author and co-authors (if any).

You must provide your full name, affiliation (degree, institution/company/University name, address, contact number and email address).

Short biography of the author (limited to 100 words).

They must be submitted before the deadlines.

All the abstracts will be reviewed by the committee and you will get an email within 24-48 hours after submission of your abstract.

All the accepted abstracts will be published in the conference proceeding books.

Submit your Abstract:

Register now:

Scientific Sessions

Session 1: Lung cancer

Cancerous tumour is a group of cancer cells that can grow into and destroy nearby tissue and can spread to other parts of the body. When cancer starts in lung cells, it is called as primary lung cancer. Cells in the lungs sometimes change and no longer grow or behave normally. These changes may lead to non-cancerous tumours such as hamartoma and papilloma.

Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC)

Session 2: Stages & Severity of Lung Diseases

There are two stages in small cell lung cancer. They are limited stage and extensive stage. Whereas non-small cell lung cancer is divided into four different stages depending upon the tumour size and location, number of nearby lymph nodes that have involved and how far the cancer has spread.


Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. It mainly affects middle-aged or older adults who is not contagious. The breathing problems gradually worsen over time and can limit normal activities, particularly if smoking exposure continues increasing breathlessness.

Cough with phlegm
Frequent chest infections
Persistent wheezing
Session 4: Causes of COPD

Long-term exposure to lung irritants that damage the lungs and the airways is the main cause of COPD. Lungs may become inflamed and narrowed. The main cause is smoking, while in few cases it may be due to air pollution, chemical fumes and dust or occur as a result of a rare genetic problem.

Inflammation is present in the lungs of people who smoke. This response to the inhaled toxins is increased in COPD, leading to tissue destruction, impairment of the defence mechanisms and disruption of the repair mechanisms. In general, the inflammatory and structural changes in the airways increase with disease severity and persist even after the smoking cessation. Apart from inflammation, two processes are involved in the pathogenesis of COPD—an imbalance between proteases and antiproteases and an imbalance between oxidants and antioxidants in the lungs.
Ciliary dysfunction or primary ciliary dyskinesia (PCD)
Pulmonary hypertension

Session 6: Surgical & Radiation Oncology

Surgical oncology is the branch of surgery applied to cancer; it focuses on the surgical management of tumours, especially cancerous tumours. As one of several modalities in the management of cancer, the specialty of surgical oncology, before modern medicine the only cancer treatment with a chance of success, has evolved in steps similar to medical oncology (pharmacotherapy for cancer), which grew out of haematology, and radiation oncology, which grew out of radiology. The proliferation of cancer centres will continue to popularize the field, as will developments in minimally invasive techniques, palliative surgery, and neo-adjuvant treatments. Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancer. A Radiation Oncologist is a specialist physician who uses ionizing radiation (such as megavoltage X-rays or radionuclides) in the treatment of cancer. Brachytherapy is an advanced cancer treatment. Radioactive seeds or sources are placed in or near a tumour itself, giving a high radiation dose to a tumour while reducing the radiation exposure in the surrounding healthy tissues. External beam therapy (EBT), also called external radiation therapy, is a method for delivering a beam or several beams of high-energy x-rays to a patient's tumour. Intraoperative radiation therapy or IORT is the application of therapeutic levels of radiation to the tumour bed while the area is exposed during surgery.

COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer | Cancer Meetings

Session 7: Comorbidities of Pulmonary Diseases

COPD, like other chronic disorders, has been associated with comorbidities that increase in number and severity with age. Comorbidities increase the risk for exacerbations and increase the risk of mortality. Over 80% of patients with COPD were estimated to have at least one comorbid chronic condition. Comorbidities like diabetes mellitus, cardiac disease, osteoporosis, hypertension, cachexia, sleep disturbance, and psychological disorders are commonly reported in patients with chronic obstructive pulmonary disease (COPD). Tobacco smoking is main risk factor for many of these comorbidities as well as for COPD.

COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer | Cancer Meetings

Session 8: Lung Diseases, Cancer & its Epidemiology

Chronic obstructive pulmonary disease is responsible for early mortality, high death rates and significant cost to health systems. The projection for 2020 indicates that COPD will be the third leading cause of death in the world.  Active smoking remains the main risk factor, but other factors such as occupational factors, infections and the role of air pollution also play a major role. Prevalence of COPD varies according to the country, age and sex. The major challenge in the coming years will be to prevent onset of smoking along with early detection of the disease in the population. An estimated 328 million people have COPD worldwide and in 15 years, COPD is expected to become the leading cause of death worldwide.


The first and important step in diagnosing COPD is a thorough evaluation by an experienced doctor. There are different types of breathing tests that can be done during pulmonary function testing which helps the doctor to understand the severity of disease. Diagnosis of COPD involves:
Lung diffusion tests
Alpha-1- antitrypsin deficiency screening
Body plethysmography
Complete blood count
Pulse oximetry
Arterial blood gases
Chest x ray
CT scan

Session 10: Clinical Trials on COPD

Drug-treatment trials have allowed useful advances to be made in the treatment and diagnosis of chronic obstructive pulmonary disease (COPD). The two main clinical trial designs are randomized controlled trials (RCTs) and observational studies.  RCTs are generally considered to provide more robust evidence than that obtained from observational studies. However, well-designed comparator controlled RCTs, although successful, have been shown to have some limitations, such as a lack of generalizability. Observational studies can generate valuable data.


Session 11: Cancer Biology & Genetics


Cancer is caused when cells within the body accumulate genetic mutations and start to grow in an uncontrolled manner. Understanding how cancer develops and progresses, including how gene mutations drive the growth and spread of cancer cells, and how tumors interact with their surrounding environment, is vital for the discovery of new targeted cancer treatments.

Tumor Biology

Cancer Epigenetics

Oncogenes & Proto-oncogenes

Tumor Suppressor Genes

About one-third of lung cancer patients are diagnosed with localized disease that may be treated by either surgical resection or, if the patient is not a candidate for full surgical resection, with definitive radiotherapy Another third of patients have disease that has already spread to the lymph nodes. In these cases, radiation therapy along with chemotherapy and occasionally surgery is used.

Short acting bronchodilators
Protein kinase inhibitors
Methyl xanthine
Long acting bronchodilators

Most people have mild forms of the disease for which small therapy is needed. Even for more advanced stages of disease, effective therapy is available that can control symptoms, reduce risk of complications and exacerbations, and improve the ability to lead a healthy and active life. Treatment may differ from person to person. Treatment includes:
Smoking cessation
Phosphodiesterase-4 inhibitors
Oxygen therapy
Pulmonary rehabilitation program

Mutational analysis and genomics profiling in recent years have advanced the field of lung cancer genetics significantly. It is becoming more accepted now that the identification of genomic alterations in lung cancer can impact therapeutics, especially when the alterations represent “oncogenic drivers” in the processes of tumorigenesis. Genetic testing is now a routine part of diagnosis and staging for every patient suffering with lung cancer and COPD. Genetics plays an important role as less than 20% of smokers develop this deadly disease in their lifetime and non-smokers with a family history of cancer have an increased risk of lung cancer.


A risk factor is anything that affects a person’s chance of getting a disease. Lung cancer is the most frequent malignant neoplasm in most countries, and the main cancer-related cause of mortality worldwide. The geographic and temporal patterns of lung cancer incidence, as well as lung cancer mortality, on a population level are chiefly determined by tobacco consumption, the main aetiological factor in lung carcinogenesis.
Tobacco smoke
Exposure to radon
Exposure to asbestos
Inhaled chemicals
Air pollution
Family history


Diagnosis is the process of finding out the cause of a health problem by performing various tests.
Chest X-ray
CT scan
PET-CT scan
Bronchoscopy and biopsy
Sputum tests


Patients with chronic obstructive pulmonary disease require greater motivation to seek help when symptom changes occur and are unaware of their increased risk of developing lung cancer further. Prevention of COPD is very crucial. People with COPD have difficulty in clearing their lungs containing bacteria, dusts and other pollutants. This may lead to lung infections that may cause further damage to the lungs. With the advent of industrial control measures to minimize air levels, acute pulmonary syndromes have virtually disappeared in respective to COPD. 
Smoking cessation
Vaccinations like influenza vaccination and pneumococcal vaccine
Avoiding exposure to second-hand smoke
Protecting against chemicals, dust and fumes

Market Analysis

       Importance & Scope of Lung Cancer And COPD Conference 2019

Lung cancer

The global lung cancer therapeutics market is expected to grow significantly in the future. North America dominated the global lung cancer therapeutics market over the past few years. The high demand in the region was sustained by factors which include increasing occurrences of lung cancer and rising levels of geriatric population. Asia-Pacific is projected to foresee the highest growth rate in the global lung cancer therapeutics market over the next eight years. Lung cancer is the leading cause of death in Europe, accounting for approximately 350 million deaths annually.


Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the asthma and chronic obstructive pulmonary disease (COPD) market globally. Worldwide US continent is the largest market for COPD. A recent market assessment study shows that COPD is the major cause of death, whose prevalence is on the rise and is predicted to be the third leading cause of death globally by 2030. Increase in commonness of COPD, increment in the geriatric populace and development of the pharmaceutical business are foreseen to fuel the development of COPD treatment market in Asia Pacific.

Major Medicine Universities:


Harvard University

University of Minnesota

Pittsburgh School of Medicine

Mayo Medical School

Yale University 

John Hopkins University

The University of Oxford Stanford University

Emory University

University of Cambridge


In Asia Pacific:

The Chinese University of Hon Kong (CUHK)

Seoul National University

Tsinghua University

National Taiwan University

Peking University

Kyoto University

National University of Singapore (NUS)

Osaka University

University of Hong Kong (HKU)


Societies related to Cancer:


Translational research in Oncology

Canceropole Ile-De-France

Institut Curie-Pole Developmental Biology

Saint- Louis Hospital

Bichat- Claude Bernard Hospital

Hartmann Clinic

Texas Oncology- Paris

Gustave Roussy Institute of Oncology

Hospital Group Paris Saint- Joseph

In Asia Pacific:

Asian Cancer Foundation

Childhood Cancer International Netherlands

The Asia Pacific Prostate Society

The Max Foundation

The Asia Pacific Cancer Society Training


Irish Cancer Society

Cancer Research UK

Peter McCollum Cancer Centre

American Society of Clinical Oncology (ASCO)

International Agency for Research on Cancer (IACR)

American Association for Cancer Research

International Cancer Research Partnership (ICRP)

National Cancer Institute (NIC)

The European Cancer Organization (ECCO)


Hospitals Associated with Cancer:


Medical Excellence JAPAN

Japan Community Healthcare Organization Chukyo Hospital

Aichi Cancer Center Hospital

Kyoto University Hospital

Japanese Red Cross Nagoya Daiichi Hospital

Dokkyo Medical University Hospital

Japan Hospital Association

Aizawa Hospital

University Hospital Kumamoto University

International Medical Center of Japan


Leiden University Medical Center

Royal Cancer Hospital

King’s College Hospital

Clattlerbridge Center for Oncology

Northampton General Hospital

Cambridge University Hospitals

University of Hospital Southhampton

Central Manchester University Hospitals

Southend University Hospital

Kingston Hospitals


New York Presbyterain Hospital

Memorial Sloan Kettering Cancer Center

Mayo Clinic Rochester

MD Anderson Cancer Center, Texas

John Hopkins Hospital, Baltimore

University of Washington Medical Center

Massachusetts General Hospital

UCSF Medical Center

UCLA Medical Center

Stanford Hospital 

Organizing Committee
OCM Member
Dejan Dokic
Director, University Clinic of Pulmonology and Allergy
Saints Cyril and Methodius University of Skopje
Skopje, Macedonia
OCM Member
John Klir
Dean and Professor, Physiology
American International Medical University
Washington, USA
OCM Member
Dr. Joe Nemeth
Emergency Medicine Physician/Trauma Team Leader, McGill University Health Centre
McGill University
Kelowna, Canada
OCM Member
Javier Mauricio Giraldo Sánchez
Doctor, Internal medicine
Medicina Intensiva del Tolima UCI Honda
Bogota, Colombia
OCM Member
Dr Marousa Kouvela
Pulmonologist, Medical Manager Respiratory
Boehringer-Ingelheim Ellas
Athens, Greece
OCM Member
Baher Effat
Professor of Food and Dairy Microbiology, Food and Dairy Microbiology
National Research Centre, Cairo, Egypt.
Cario, Egypt
OCM Member
Sevgi Ciftci
Department of Microbiology
Istanbul University
Istanbul, Turkey
OCM Member
Daniela Capdepón
Owner and Medical Director, Cancer Center Campana. Monitoring and Clinical Research
Oncology Center of Buenos Aires
Buenos aires, Argentina
OCM Member
Dr. Ken H. Young
Professor, Hematopathology
University of Texas MD Anderson Cancer Center
Houston, USA
OCM Member
Ziding Feng, Ph.D.
Professor Section Chief Early Cancer Detection and Biomarkers, Department of Biostatistics, Division of Science
University of Texas MD Anderson Cancer Center
Houston, USA
OCM Member
Lyuba Varticovski
Founding Director of first Russian American Medical Association in USA, Cancer Biology
National Cancer Institute
Naples, Italy
OCM Member
Dr Sergey Suchkov
Director, Center for Personalized medicine, Sechenov University and Chair, Dept for Translational Medicine
MOSCOW Engineering Physical Institute (MEPhI), Russia
Moscow, Russia
OCM Member
Dr Inés Llamas-Ramos
Physiotherapist in Salamanca
University of Salamanca
Madrid, Spain
OCM Member
Dr. Yoshiaki Omura
President of the International College of Acupuncture & Electro-Therapeutics
International College of Acupuncture & Electro-Therapeutics
New York, USA
OCM Member
Sergey Suchkov
Russian Academy of Sciences, Saratov
Moscow, Russia
OCM Member
Samir Jaoua
Professor , Department of Microbiology
Qatar University
Al Luqta St, Qatar
Scientific Program
Renowned Speakers

Conference Venue: Best Western Premier Airporthotel Fontane Berlin,

Jonas-Lie-Straße 5-11, 15831 Berlin (Mahlow), Germany.


Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program Inquiry
General Enquiry
Sponsorship Opportunity
More details about

Terms and Conditions


Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.


Registration fees do not include insurance of any kind.


Please note that any (or) all transportation and parking is the responsibility of the registrant.


Press permission must be obtained from Allied Academies Conferences Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies Ltd is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrants account.

Cancellation, Postponement and Transfer of Registration

All cancellations or modifications of registration must be made in writing to

  • Before 90 days of the conference: Eligible for Full Refund less $100 Service Fee
  • Within 90-60 days of Conference: Eligible for 50% of payment Refund
  • Within 60 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Cancellation Policy

If Allied Academies Group cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Group event which must occur within one year from the date of cancellation.


If Allied Academies Group postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Ltd event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization if the registered person is unable to attend the event. Transfers must be made by the registered person in writing to
. Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies Ltd if the person is unable to attend one of the conferences.

However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies Ltd will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies Ltd, including the inability to obtain a visa.

Refund Policy

If the registrant is unable to attend and is not able to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

Accommodation Cancellation Policy

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies Ltd will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

Highlights from last year's Convention

Authorization Policy

Copyright © 2021-2022 Allied Academies, All Rights Reserved.